BioSpace News Archive

BioMidwest

RIVERMARK MEDICAL ANNOUNCES SUCCESSFUL FIRST-IN-HUMAN USE OF ITS FLOSTENT SYSTEM FOR SYMPTOMATIC BPH

Rivermark MedicalTM, a company dedicated to developing first-line device therapy for benign prostatic hyperplasia (BPH), announced today the successful first-in-human (FIH) use of its FloStentTM System as part of the Company’s RAPID-1 FIH clinical study.

January 10, 2023
·
3 min read
Biotech Beach

Cardiff Oncology to Present at B. Riley Securities’ 3rd Annual Oncology Conference

Cardiff Oncology, Inc. today announced that company management will participate in a fireside chat at B. Riley Securities’ 3rd Annual Oncology Conference, which is taking place virtually from January 18 – 19, 2023.

January 10, 2023
·
1 min read
Deals

BIOLASE INC. ANNOUNCES PRICING OF APPROXIMATELY $9.75 MILLION UNDERWRITTEN PUBLIC OFFERING

BIOLASE, Inc. today announced the pricing of an underwritten public offering consisting of 16,453,569 shares of its common stock and pre-funded warrants to purchase 11,403,571 shares of common stock at a public offering price of $0.35 per share.

January 10, 2023
·
4 min read
Pharm Country

Glenmark Pharmaceuticals launches Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials

Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce it has launched Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials, the generic version of Bumex® 1 Injection, 0.25 mg/mL, of Validus Pharmaceuticals LLC.

January 10, 2023
·
2 min read
Business

Neurotech Pharmaceuticals, Inc. Expands Executive Team with the Appointment of Scott Hunter as Chief Commercial Officer

Neurotech Pharmaceuticals, Inc., a clinical stage biotech company, today announced the expansion of its executive team with the appointment of Scott Hunter as Chief Commercial Officer bringing two decades of eyecare experience across both rare disease and specialty markets.

January 10, 2023
·
4 min read
Business

Inogen Announces Preliminary Fourth Quarter and Full Year 2022 Revenue Within Company Expectations

Inogen, Inc. today announced unaudited preliminary revenue results for the fourth quarter and the full year ended December 31, 2022.

January 10, 2023
·
6 min read
Drug Development

Alto Neuroscience Announces Positive Results for ALTO-100 in Phase 2 Study Supporting Advancement of First-in-Class Mechanism for Treating Depression

Alto Neuroscience Inc. today reported results from its Phase 2a study of ALTO-100, demonstrating clear evidence of efficacy and favorable safety in patients with MDD.

January 10, 2023
·
5 min read
Lone Star Bio

Integer to Exhibit at NANS 2023 Annual Meeting

Integer Holdings Corporation, a leading medical device outsource manufacturer, will exhibit at the 26th North American Neuromodulation Society Annual Meeting at Caesars Palace Convention Center in Las Vegas, Nevada, from Jan. 12 – 14, 2023, joining medtech leaders and innovators from around the world.

January 10, 2023
·
2 min read
Decoding Brain Arteriovenous Malformations in the Asian Population: A Chinese Neurosurgical Journal Study

Brain arteriovenous malformation is the abnormal entanglement of arteries and veins in the brain, which disrupts the normal flow of blood and can lead to hemorrhage, seizures, and neurological impairment in affected individuals.

January 10, 2023
·
3 min read
Business

ValGenesis and QualiTech Announce Strategic Partnership for Digital Validation Solutions and Services in Greece

ValGenesis, Inc and QualiTech Engineering and Compliance have announced a strategic partnership to deliver best-in-class digital validation solutions and services for life science companies in Greece.

January 10, 2023
·
3 min read